Statement: Patients must have already participated in a specific clinical study to participate in the primary trial.
Primary_evidence: Inclusion Criteria:   Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participated in the preceding phase II clinical study